Euro-Med Laboratories Phil Valuation

Q: What is the Fair Price of EURO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

EURO (₱0.8) is trading above our estimate of [[fair value]] (₱0.74)

Is EURO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EURO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EURO (₱0.8) is trading above our estimate of fair value (₱0.74)

Significantly Below Fair Value: EURO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EURO?

Key metric: As EURO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EURO. This is calculated by dividing EURO's market cap by their current earnings.
What is EURO's PE Ratio?
PE Ratio	10.2x
Earnings	₱323.72m
Market Cap	₱3.29b

EURO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	6.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does EURO's PE Ratio compare to its peers?

The above table shows the PE ratio for EURO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	77.1x
530477 Vikram Thermo (India)	138.2x	n/a	₹5.4b
A004720 PharmGen Science	148.3x	n/a	₩82.4b
DADI Dar Al Dawa Development and Investment	13.5x	n/a	د.أ44.8m
1J5 Hyphens Pharma International	8.3x	6.2%	S$86.5m
EURO Euro-Med Laboratories Phil	10.2x	n/a	₱3.3b

Price-To-Earnings vs Peers: EURO is good value based on its Price-To-Earnings Ratio (10.2x) compared to the peer average (77.1x).

Price to Earnings Ratio vs Industry

How does EURO's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

13 Companies	Price / Earnings	Estimated Growth	Market Cap

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: EURO is good value based on its Price-To-Earnings Ratio (10.2x) compared to the Asian Pharmaceuticals industry average (25.4x).

Price to Earnings Ratio vs Fair Ratio

What is EURO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EURO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EURO's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.